Table 4.

Existing studies describing the COVID-19 pandemic impact on cervical cancer survival.

First Author (Year)	Conclusions
Gupta et al. (2021) [30]	A 2.52% to 3.80% increase in cervical cancer-related deaths with treatment delays ranging from 9 weeks to 6 months.
Kregting et al. (2021) [31]	An increase of 2.0, 0.3, and 2.5 cancer deaths per 100,000 individuals in 10 years.
Matsuo et al. (2021) [32]	Wait-time of 6.1–9.8 weeks for cervical cancer treatment was not associated with increased risk of all-cause mortality compared to a wait-time of 6 weeks.
Matsuo et al. (2021) [33]	In women with early-stage cervical cancer, an 8-week delay for hysterectomy may not be related with short-term disease recurrence and shorter DFS.
Davies et al. (2022) [34]	Over the next 3 years, there is anticipated considerable rise in newly-diagnosed cervical cancer cases. Increased surgical capacity might alleviate this burden with no significant morbidity or mortality increase.
Matsuo et al. (2021) [35]	Postponing hysterectomy for 6–8 weeks is appropriate for women with early-stage cervical cancer in centers or areas with a high prevalence of COVID-19 illness and has no detrimental effect on survival.